Tagged with UK

UK First published in the November 2025 edition of DIA’s Global Forum, this piece by Jane Morrin O’Rourke, Naho Yamazaki, Becky Purvis (HRA) and Mandy Budwal-Jagait, Jason Wakelin-Smith and Kingyin Lee (MHRA) dives into one of the UK’s most urgent research challenges: how to make clinical trials genuinely inclusive. The authors…

UK Originally published in the October 2025 edition of DIA’s Global Forum magazine, this article — authored by Mandy Budwal-Jagait, Kingyin Lee, Maria Urdaneta-Abate, Hedwig Ganguly, Rachel Mead, and Louisa Obillo of the UK Medicines and Healthcare products Regulatory Agency (MHRA), together with Catherine Blewett of the Health Research Authority (HRA)…

Global As chief development officer of Moderna, Dr Melanie Ivarsson OBE spearheaded the rapid development of a COVID-19 vaccine that helped the world emerge from the pandemic. Now back in the UK and drawing on over 25 years of clinical development leadership across Lilly, Pfizer, Takeda, and Moderna, Dr Ivarsson recently…

UK Writing in the September 2025 edition of DIA’s Global Forum magazine, Janet Messer, Catherine Blewett, and Naho Yamazaki of the UK Health Research Authority (HRA) and Stephen Lam, Crina Cacou, Anthony Carter, and Sara Rajendran of the UK Medicines and Healthcare products Regulatory Agency (MHRA), lay out how UK clinical…

UK Europe risks “slow death” in innovation unless it builds its own Silicon Valley, argues digital health investor Laurent van Lerberghe. With Macron pushing Anglo-French tech sovereignty, the UK and France have the talent, capital, and healthcare ecosystems to lead. By linking their world-class clusters, aligning regulation, and pooling investment, they…

UK The latest from UK pharma, including teething troubles and industry pushback for the country’s new life sciences strategy; Sanofi snapping up UK vaccines outfit Vicebio for USD 1.6 billion; and why AstraZeneca’s latest US manufacturing investment does little to ease fears that the British firm might choose to relocate across…

UK A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian biotech EsoBiotec and its exit from neuroscience; GSK’s liver disease asset deal with Boston Pharmaceuticals, and CellCentric’s US expansion.  …

United Kingdom UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages the NHS in England, it has now decided to eliminate it altogether. In a move that Starmer said would increase…

Japan Japan was once a global leader in life sciences innovation, introducing about a third of the world’s new drugs in the 1980s, but this positioning slipped following decades of economic stagnation compounded by a conservative regulatory regime. However recent regulatory reforms have brought a more positive outlook and sparked a…

Global Throughout the year PharmaBoardroom has talked to pharma and biotech executives and life sciences opinion leaders across the globe, gathering vital insights into local markets, learning about promising new therapies, and examining the broader trends shaping the industry. Here is a selection of some of the year’s most-read interviews.  …

Japan A summary of some of the biggest stories coming out of Japan’s pharma industry, including Teva’s divestment of joint venture Teva-Takeda; GE HealthCare’s takeover of Nihon Medi-Physics; Takeda’s blood cancer anemia drug licensing deal with Keros, and Astellas’ new cell therapy research site in Japan.   Pharma firm Teva to…

UK Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional cash to R&D, and incentivise manufacturing through a new GBP 520 million Life Sciences Innovative Manufacturing Fund (LSIMF).   Addressing…